TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE) filed its financial and operating results today for its fiscal quarter ended June 30, 2014.
Highlights for the quarter include:
* Conducted non-brokered private placements yielding gross proceeds of $1,244,560, which together with financings closed in fiscal Q4 2014, is sufficient to fund Phase I clinical trials for Antibe’s lead drug, ATB-346
Help employers find you! Check out all the jobs and post your resume.
